Cara Therapeutics, Inc. (CARA)

Market Cap	24.33M
Revenue (ttm)	7.14M
Net Income (ttm)	-70.87M
Shares Out	1.52M
EPS (ttm)	-46.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,047
Open	16.17
Previous Close	16.65
Day's Range	15.84 - 16.56
52-Week Range	5.28 - 31.32
Beta	0.41
Analysts	Hold
Price Target	12.00 (-24.81%)
Earnings Date	May 12, 2025

About CARA

Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: CARA
• Website: https://www.caratherapeutics.com

Financial Performance

In 2024, Cara Therapeutics's revenue was $7.14 million, a decrease of -65.96% compared to the previous year's $20.97 million. Losses were -$70.87 million, -40.20% less than in 2023.

Analyst Summary

According to 3 analysts, the average rating for CARA stock is "Hold." The 12-month stock price target is $12.0, which is a decrease of -24.81% from the latest price.

Price Target

$12.0

(-24.81% downside)

Analyst Consensus: Hold